{"product_id":"lgd-4033-50x10mg","title":"LGD-4033 100x10mg","description":"\u003cp\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003cmeta charset=\"UTF-8\"\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"54\" data-end=\"564\"\u003e\u003cstrong\u003eLGD-4033 \u003c\/strong\u003eis an oral, non-steroidal \u003cstrong data-start=\"122\" data-end=\"170\"\u003eselective androgen receptor modulator (SARM)\u003c\/strong\u003e designed to produce \u003cstrong data-start=\"191\" data-end=\"230\"\u003eanabolic effects in muscle and bone\u003c\/strong\u003e with comparatively \u003cstrong data-start=\"250\" data-end=\"287\"\u003eless stimulation of prostate\/skin\u003c\/strong\u003e than testosterone. It binds the \u003cstrong data-start=\"320\" data-end=\"346\"\u003eandrogen receptor (AR)\u003c\/strong\u003e, recruits co-activators in muscle\/bone, and avoids \u003cstrong data-start=\"398\" data-end=\"415\"\u003e5-α reduction\u003c\/strong\u003e and \u003cstrong data-start=\"420\" data-end=\"437\"\u003earomatization\u003c\/strong\u003e. LGD-4033 is \u003cstrong data-start=\"451\" data-end=\"475\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e; it remains an investigational agent and is \u003cstrong data-start=\"520\" data-end=\"542\"\u003eprohibited by WADA\u003c\/strong\u003e as an anabolic agent.\u003c\/p\u003e\n\u003chr data-start=\"566\" data-end=\"569\"\u003e\n\u003ch3 data-start=\"571\" data-end=\"630\"\u003eAdditional Benefits of LGD-4033 Now Under Investigation\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"632\" data-end=\"2790\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"632\" data-end=\"660\"\u003e\n\u003ctr data-start=\"632\" data-end=\"660\"\u003e\n\u003cth data-start=\"632\" data-end=\"642\" data-col-size=\"md\"\u003eBenefit\u003c\/th\u003e\n\u003cth data-start=\"642\" data-end=\"660\" data-col-size=\"xl\"\u003eKey take-aways\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"671\" data-end=\"2790\"\u003e\n\u003ctr data-start=\"671\" data-end=\"990\"\u003e\n\u003ctd data-start=\"671\" data-end=\"720\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"673\" data-end=\"719\"\u003e1 Lean-mass accrual in humans (short term)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"720\" data-end=\"990\" data-col-size=\"xl\"\u003eIn a 21-day, randomized, placebo-controlled trial in healthy men, \u003cstrong data-start=\"788\" data-end=\"847\"\u003edose-dependent increases in fat-free mass (~0.6–1.5 kg)\u003c\/strong\u003e occurred without major fluid retention; strength\/power showed favorable trends. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Gerontology: Medical Sciences; JCEM\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"991\" data-end=\"1240\"\u003e\n\u003ctd data-start=\"991\" data-end=\"1022\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"993\" data-end=\"1021\"\u003e2 Functional performance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1022\" data-end=\"1240\" data-col-size=\"xl\"\u003eImprovements in \u003cstrong data-start=\"1040\" data-end=\"1062\"\u003eleg-press strength\u003c\/strong\u003e and \u003cstrong data-start=\"1067\" data-end=\"1088\"\u003estair-climb power\u003c\/strong\u003e have been reported in small studies—consistent with anabolic signaling translating to function. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Medicine \u0026amp; Science in Sports \u0026amp; Exercise\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1241\" data-end=\"1509\"\u003e\n\u003ctd data-start=\"1241\" data-end=\"1274\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1243\" data-end=\"1273\"\u003e3 Anti-catabolic potential\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1274\" data-end=\"1509\" data-col-size=\"xl\"\u003eIn preclinical atrophy models (castration, hind-limb unloading), LGD-4033 \u003cstrong data-start=\"1350\" data-end=\"1374\"\u003epreserves muscle CSA\u003c\/strong\u003e and \u003cstrong data-start=\"1379\" data-end=\"1432\"\u003ereduces ubiquitin-ligase (MAFbx\/MuRF1) expression\u003c\/strong\u003e. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;FASEB Journal; American Journal of Physiology–Endocrinology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1510\" data-end=\"1742\"\u003e\n\u003ctd data-start=\"1510\" data-end=\"1540\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1512\" data-end=\"1539\"\u003e4 Bone-anabolic signals\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1540\" data-end=\"1742\" data-col-size=\"xl\"\u003eIn rodent osteopenia, LGD-class SARMs \u003cstrong data-start=\"1580\" data-end=\"1623\"\u003eincrease BMD and biomechanical strength\u003c\/strong\u003e, with \u003cstrong data-start=\"1630\" data-end=\"1649\"\u003eosteocalcin\/ALP\u003c\/strong\u003e rises and limited prostate stimulation. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Bone and Mineral Research\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1743\" data-end=\"1975\"\u003e\n\u003ctd data-start=\"1743\" data-end=\"1799\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1745\" data-end=\"1798\"\u003e5 Recovery after immobilization\/illness (concept)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"1799\" data-end=\"1975\" data-col-size=\"xl\"\u003eEarly translational work explores \u003cstrong data-start=\"1835\" data-end=\"1877\"\u003epost-fracture and post-hospitalization\u003c\/strong\u003e lean-mass restoration with exercise\/rehab. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Geriatrics \u0026amp; Gerontology International\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1976\" data-end=\"2179\"\u003e\n\u003ctd data-start=\"1976\" data-end=\"2008\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"1978\" data-end=\"2007\"\u003e6 Erythropoiesis (modest)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2008\" data-end=\"2179\" data-col-size=\"xl\"\u003eAndrogen-axis engagement may \u003cstrong data-start=\"2039\" data-end=\"2079\"\u003eslightly raise hemoglobin\/hematocrit\u003c\/strong\u003e, below testosterone’s magnitude—requires monitoring in at-risk patients. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Hematology\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2180\" data-end=\"2373\"\u003e\n\u003ctd data-start=\"2180\" data-end=\"2205\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2182\" data-end=\"2204\"\u003e7 Oral convenience\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2205\" data-end=\"2373\" data-col-size=\"xl\"\u003e\n\u003cstrong data-start=\"2207\" data-end=\"2233\"\u003eOnce-daily oral dosing\u003c\/strong\u003e with a long half-life supports adherence in trials compared with injectable anabolics. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Clinical Pharmacology \u0026amp; Therapeutics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2374\" data-end=\"2601\"\u003e\n\u003ctd data-start=\"2374\" data-end=\"2401\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2376\" data-end=\"2400\"\u003e8 Tissue selectivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2401\" data-end=\"2601\" data-col-size=\"xl\"\u003eNon-steroidal AR binding yields \u003cstrong data-start=\"2435\" data-end=\"2475\"\u003elower sebaceous\/prostate stimulation\u003c\/strong\u003e per unit anabolic effect versus 17-α-alkylated androgens. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Journal of Pharmacology \u0026amp; Experimental Therapeutics\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2602\" data-end=\"2790\"\u003e\n\u003ctd data-start=\"2602\" data-end=\"2647\" data-col-size=\"md\"\u003e\u003cstrong data-start=\"2604\" data-end=\"2646\"\u003e9 Combination with resistance training\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"2647\" data-end=\"2790\" data-col-size=\"xl\"\u003ePreliminary data suggest \u003cstrong data-start=\"2674\" data-end=\"2692\"\u003eadditive gains\u003c\/strong\u003e when paired with structured training and adequate protein intake. \u0026lt;br\/\u0026gt;\u0026lt;em\u0026gt;Sports Medicine\u0026lt;\/em\u0026gt;\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"2792\" data-end=\"2795\"\u003e\n\u003ch2 data-start=\"2797\" data-end=\"2832\"\u003e2. Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2834\" data-end=\"2869\"\u003e2.1 Receptor Pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"2870\" data-end=\"3219\"\u003eLGD-4033 binds \u003cstrong data-start=\"2885\" data-end=\"2891\"\u003eAR\u003c\/strong\u003e → nuclear translocation → \u003cstrong data-start=\"2918\" data-end=\"2946\"\u003eARE-driven transcription\u003c\/strong\u003e. In muscle, it up-regulates \u003cstrong data-start=\"2975\" data-end=\"2989\"\u003emTOR\/IGF-1\u003c\/strong\u003enetworks and down-regulates \u003cstrong data-start=\"3018\" data-end=\"3031\"\u003eatrogenes\u003c\/strong\u003e; in bone, it enhances \u003cstrong data-start=\"3054\" data-end=\"3077\"\u003eosteoblast activity\u003c\/strong\u003e and may suppress \u003cstrong data-start=\"3095\" data-end=\"3117\"\u003eosteoclastogenesis\u003c\/strong\u003eindirectly. Lack of aromatization\/5-α reduction underlies its \u003cstrong data-start=\"3180\" data-end=\"3202\"\u003etissue selectivity\u003c\/strong\u003e vs testosterone.\u003c\/p\u003e\n\u003ch3 data-start=\"3221\" data-end=\"3248\"\u003e2.2 Down-stream Biology\u003c\/h3\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3250\" data-end=\"3599\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3250\" data-end=\"3292\"\u003e\n\u003ctr data-start=\"3250\" data-end=\"3292\"\u003e\n\u003cth data-start=\"3250\" data-end=\"3260\" data-col-size=\"sm\"\u003ePathway\u003c\/th\u003e\n\u003cth data-start=\"3260\" data-end=\"3281\" data-col-size=\"md\"\u003eFunctional outcome\u003c\/th\u003e\n\u003cth data-start=\"3281\" data-end=\"3292\" data-col-size=\"sm\"\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3307\" data-end=\"3599\"\u003e\n\u003ctr data-start=\"3307\" data-end=\"3386\"\u003e\n\u003ctd data-start=\"3307\" data-end=\"3323\" data-col-size=\"sm\"\u003eAR → mTOR\/S6K\u003c\/td\u003e\n\u003ctd data-start=\"3323\" data-end=\"3367\" data-col-size=\"md\"\u003e↑ protein synthesis, myofiber hypertrophy\u003c\/td\u003e\n\u003ctd data-start=\"3367\" data-end=\"3386\" data-col-size=\"sm\"\u003eSkeletal muscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3387\" data-end=\"3454\"\u003e\n\u003ctd data-start=\"3387\" data-end=\"3416\" data-col-size=\"sm\"\u003eAR → Wnt\/β-catenin\/Osterix\u003c\/td\u003e\n\u003ctd data-start=\"3416\" data-end=\"3446\" data-col-size=\"md\"\u003e↑ osteoblastogenesis, ↑ BMD\u003c\/td\u003e\n\u003ctd data-start=\"3446\" data-end=\"3454\" data-col-size=\"sm\"\u003eBone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3455\" data-end=\"3532\"\u003e\n\u003ctd data-start=\"3455\" data-end=\"3482\" data-col-size=\"sm\"\u003e↓ FoxO\/ubiquitin ligases\u003c\/td\u003e\n\u003ctd data-start=\"3482\" data-end=\"3512\" data-col-size=\"md\"\u003e↓ proteolysis (MAFbx\/MuRF1)\u003c\/td\u003e\n\u003ctd data-start=\"3512\" data-end=\"3532\" data-col-size=\"sm\"\u003eCatabolic states\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3533\" data-end=\"3599\"\u003e\n\u003ctd data-start=\"3533\" data-end=\"3563\" data-col-size=\"sm\"\u003eMyostatin\/activin crosstalk\u003c\/td\u003e\n\u003ctd data-start=\"3563\" data-end=\"3589\" data-col-size=\"md\"\u003eFavors anabolic balance\u003c\/td\u003e\n\u003ctd data-start=\"3589\" data-end=\"3599\" data-col-size=\"sm\"\u003eMuscle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3601\" data-end=\"3604\"\u003e\n\u003ch2 data-start=\"3606\" data-end=\"3628\"\u003e3. Pharmacokinetics\u003c\/h2\u003e\n\u003cul data-start=\"3630\" data-end=\"4088\"\u003e\n\u003cli data-start=\"3630\" data-end=\"3650\"\u003e\n\u003cp data-start=\"3632\" data-end=\"3650\"\u003e\u003cstrong data-start=\"3632\" data-end=\"3642\"\u003eRoute:\u003c\/strong\u003e Oral.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3651\" data-end=\"3743\"\u003e\n\u003cp data-start=\"3653\" data-end=\"3743\"\u003e\u003cstrong data-start=\"3653\" data-end=\"3667\"\u003eHalf-life:\u003c\/strong\u003e \u003cstrong data-start=\"3668\" data-end=\"3680\"\u003e~24–36 h\u003c\/strong\u003e, allowing \u003cstrong data-start=\"3691\" data-end=\"3705\"\u003eonce-daily\u003c\/strong\u003e dosing; \u003cstrong data-start=\"3714\" data-end=\"3740\"\u003esteady state ~5–7 days\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3744\" data-end=\"3831\"\u003e\n\u003cp data-start=\"3746\" data-end=\"3831\"\u003e\u003cstrong data-start=\"3746\" data-end=\"3773\"\u003eAbsorption\/food effect:\u003c\/strong\u003e Good oral bioavailability; minor food effects reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3832\" data-end=\"3917\"\u003e\n\u003cp data-start=\"3834\" data-end=\"3917\"\u003e\u003cstrong data-start=\"3834\" data-end=\"3849\"\u003eMetabolism:\u003c\/strong\u003e Hepatic oxidative and conjugative pathways; high protein binding.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3918\" data-end=\"3978\"\u003e\n\u003cp data-start=\"3920\" data-end=\"3978\"\u003e\u003cstrong data-start=\"3920\" data-end=\"3936\"\u003eElimination:\u003c\/strong\u003e Renal\/hepatic clearance of metabolites.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3979\" data-end=\"4088\"\u003e\n\u003cp data-start=\"3981\" data-end=\"4088\"\u003e\u003cstrong data-start=\"3981\" data-end=\"4002\"\u003eDoping detection:\u003c\/strong\u003e \u003cstrong data-start=\"4003\" data-end=\"4028\"\u003eLong-term metabolites\u003c\/strong\u003e enable detection \u003cstrong data-start=\"4046\" data-end=\"4065\"\u003eweeks after use\u003c\/strong\u003e in anti-doping assays.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4090\" data-end=\"4093\"\u003e\n\u003ch2 data-start=\"4095\" data-end=\"4140\"\u003e4. Pre-clinical and Translational Evidence\u003c\/h2\u003e\n\u003ch3 data-start=\"4142\" data-end=\"4170\"\u003e4.1 Healthy Volunteers\u003c\/h3\u003e\n\u003cp data-start=\"4171\" data-end=\"4410\"\u003e21-day RCT showed \u003cstrong data-start=\"4189\" data-end=\"4233\"\u003edose-proportional increases in lean mass\u003c\/strong\u003e, small strength\/power improvements, and \u003cstrong data-start=\"4274\" data-end=\"4323\"\u003ereversible suppression of LH\/FSH\/testosterone\u003c\/strong\u003e with \u003cstrong data-start=\"4329\" data-end=\"4346\"\u003eHDL reduction\u003c\/strong\u003e; liver enzymes were largely within reference in the short term.\u003c\/p\u003e\n\u003ch3 data-start=\"4412\" data-end=\"4454\"\u003e4.2 Sarcopenia\/Frailty \u0026amp; Orthopedics\u003c\/h3\u003e\n\u003cp data-start=\"4455\" data-end=\"4604\"\u003eConcept studies target \u003cstrong data-start=\"4478\" data-end=\"4494\"\u003eolder adults\u003c\/strong\u003e and \u003cstrong data-start=\"4499\" data-end=\"4516\"\u003epost-fracture\u003c\/strong\u003e patients to accelerate \u003cstrong data-start=\"4540\" data-end=\"4564\"\u003erehabilitation gains\u003c\/strong\u003e; definitive phase-2\/3 data are lacking.\u003c\/p\u003e\n\u003ch3 data-start=\"4606\" data-end=\"4627\"\u003e4.3 Bone Health\u003c\/h3\u003e\n\u003cp data-start=\"4628\" data-end=\"4805\"\u003eRodent data demonstrate \u003cstrong data-start=\"4652\" data-end=\"4677\"\u003espine\/femur BMD gains\u003c\/strong\u003e and improved \u003cstrong data-start=\"4691\" data-end=\"4720\"\u003ethree-point bend strength\u003c\/strong\u003e, supporting exploration in \u003cstrong data-start=\"4748\" data-end=\"4764\"\u003eosteoporosis\u003c\/strong\u003e or \u003cstrong data-start=\"4768\" data-end=\"4804\"\u003eglucocorticoid-induced bone loss\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cblockquote data-start=\"4807\" data-end=\"4975\"\u003e\n\u003cp data-start=\"4809\" data-end=\"4975\"\u003e\u003cstrong data-start=\"4809\" data-end=\"4835\"\u003eEvidence quality note:\u003c\/strong\u003e Human data remain \u003cstrong data-start=\"4854\" data-end=\"4878\"\u003eshort-term and small\u003c\/strong\u003e. Long-term \u003cstrong data-start=\"4890\" data-end=\"4950\"\u003eefficacy and safety (CV, hepatic, prostate, psychiatric)\u003c\/strong\u003e are \u003cstrong data-start=\"4955\" data-end=\"4974\"\u003enot established\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003chr data-start=\"4977\" data-end=\"4980\"\u003e\n\u003ch2 data-start=\"4982\" data-end=\"5015\"\u003e5. Emerging Clinical Interests\u003c\/h2\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"5017\" data-end=\"5446\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"5017\" data-end=\"5055\"\u003e\n\u003ctr data-start=\"5017\" data-end=\"5055\"\u003e\n\u003cth data-start=\"5017\" data-end=\"5025\" data-col-size=\"sm\"\u003eField\u003c\/th\u003e\n\u003cth data-start=\"5025\" data-end=\"5037\" data-col-size=\"md\"\u003eRationale\u003c\/th\u003e\n\u003cth data-start=\"5037\" data-end=\"5055\" data-col-size=\"sm\"\u003eCurrent status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"5070\" data-end=\"5446\"\u003e\n\u003ctr data-start=\"5070\" data-end=\"5167\"\u003e\n\u003ctd data-start=\"5070\" data-end=\"5093\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5072\" data-end=\"5092\"\u003eSarcopenia\/aging\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5093\" data-end=\"5144\" data-col-size=\"md\"\u003eOral anabolic with less prostate\/steroid baggage\u003c\/td\u003e\n\u003ctd data-start=\"5144\" data-end=\"5167\" data-col-size=\"sm\"\u003eEarly translational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5168\" data-end=\"5259\"\u003e\n\u003ctd data-start=\"5168\" data-end=\"5202\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5170\" data-end=\"5201\"\u003eHip-fracture\/immobilization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5202\" data-end=\"5241\" data-col-size=\"md\"\u003eLean-mass restoration to speed rehab\u003c\/td\u003e\n\u003ctd data-start=\"5241\" data-end=\"5259\" data-col-size=\"sm\"\u003ePilot concepts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5260\" data-end=\"5360\"\u003e\n\u003ctd data-start=\"5260\" data-end=\"5282\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5262\" data-end=\"5281\"\u003eCancer\/cachexia\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5282\" data-end=\"5332\" data-col-size=\"md\"\u003eAppetite-neutral anabolic (vs ghrelin mimetics)\u003c\/td\u003e\n\u003ctd data-start=\"5332\" data-end=\"5360\" data-col-size=\"sm\"\u003ePre-clinical\/feasibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5361\" data-end=\"5446\"\u003e\n\u003ctd data-start=\"5361\" data-end=\"5390\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"5363\" data-end=\"5389\"\u003eOsteoporosis (adjunct)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"5390\" data-end=\"5430\" data-col-size=\"md\"\u003eBone-anabolic\/anti-resorptive balance\u003c\/td\u003e\n\u003ctd data-start=\"5430\" data-end=\"5446\" data-col-size=\"sm\"\u003ePre-clinical\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5448\" data-end=\"5451\"\u003e\n\u003ch2 data-start=\"5453\" data-end=\"5482\"\u003e6. Safety and Tolerability\u003c\/h2\u003e\n\u003cul data-start=\"5484\" data-end=\"6409\"\u003e\n\u003cli data-start=\"5484\" data-end=\"5662\"\u003e\n\u003cp data-start=\"5486\" data-end=\"5662\"\u003e\u003cstrong data-start=\"5486\" data-end=\"5512\"\u003eEndocrine suppression:\u003c\/strong\u003e \u003cstrong data-start=\"5513\" data-end=\"5578\"\u003eDose-dependent LH\/FSH and total\/free testosterone suppression\u003c\/strong\u003e within 3 weeks; generally \u003cstrong data-start=\"5605\" data-end=\"5619\"\u003ereversible\u003c\/strong\u003e over several weeks post-discontinuation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5663\" data-end=\"5772\"\u003e\n\u003cp data-start=\"5665\" data-end=\"5772\"\u003e\u003cstrong data-start=\"5665\" data-end=\"5676\"\u003eLipids:\u003c\/strong\u003e \u003cstrong data-start=\"5677\" data-end=\"5697\"\u003eHDL-C reductions\u003c\/strong\u003e (often 10–25%) and occasional \u003cstrong data-start=\"5728\" data-end=\"5740\"\u003e↑ TG\/LDL\u003c\/strong\u003e; monitor cardiovascular risk.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5773\" data-end=\"5988\"\u003e\n\u003cp data-start=\"5775\" data-end=\"5988\"\u003e\u003cstrong data-start=\"5775\" data-end=\"5787\"\u003eHepatic:\u003c\/strong\u003e Short trials showed \u003cstrong data-start=\"5808\" data-end=\"5841\"\u003eminimal median ALT\/AST change\u003c\/strong\u003e, but \u003cstrong data-start=\"5847\" data-end=\"5904\"\u003ecase reports of cholestatic\/drug-induced liver injury\u003c\/strong\u003e exist from real-world\/“supplement” use—source quality and co-ingestants confound.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5989\" data-end=\"6080\"\u003e\n\u003cp data-start=\"5991\" data-end=\"6080\"\u003e\u003cstrong data-start=\"5991\" data-end=\"6010\"\u003eCardiovascular:\u003c\/strong\u003e No outcome data; theoretical risk via \u003cstrong data-start=\"6049\" data-end=\"6077\"\u003eatherogenic lipid shifts\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6081\" data-end=\"6158\"\u003e\n\u003cp data-start=\"6083\" data-end=\"6158\"\u003e\u003cstrong data-start=\"6083\" data-end=\"6099\"\u003eHematologic:\u003c\/strong\u003e Mild \u003cstrong data-start=\"6105\" data-end=\"6121\"\u003e↑ hematocrit\u003c\/strong\u003e possible—monitor if baseline high.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6159\" data-end=\"6266\"\u003e\n\u003cp data-start=\"6161\" data-end=\"6266\"\u003e\u003cstrong data-start=\"6161\" data-end=\"6175\"\u003eOther AEs:\u003c\/strong\u003e Headache, nausea, dry mouth, musculoskeletal aches, insomnia\/irritability in some users.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6267\" data-end=\"6409\"\u003e\n\u003cp data-start=\"6269\" data-end=\"6409\"\u003e\u003cstrong data-start=\"6269\" data-end=\"6291\"\u003eDrug interactions:\u003c\/strong\u003e Potential with drugs affecting hepatic enzymes\/lipids; avoid \u003cstrong data-start=\"6353\" data-end=\"6381\"\u003econcomitant hepatotoxins\u003c\/strong\u003e and \u003cstrong data-start=\"6386\" data-end=\"6399\"\u003epregnancy\u003c\/strong\u003e exposure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"6411\" data-end=\"6440\"\u003e\u003cstrong data-start=\"6411\" data-end=\"6440\"\u003eComparative safety matrix\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv class=\"_tableContainer_1rjym_1\"\u003e\n\u003cdiv class=\"_tableWrapper_1rjym_13 group flex w-fit flex-col-reverse\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6442\" data-end=\"7062\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6442\" data-end=\"6528\"\u003e\n\u003ctr data-start=\"6442\" data-end=\"6528\"\u003e\n\u003cth data-start=\"6442\" data-end=\"6452\" data-col-size=\"sm\"\u003eConcern\u003c\/th\u003e\n\u003cth data-start=\"6452\" data-end=\"6467\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6454\" data-end=\"6466\"\u003eLGD-4033\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6467\" data-end=\"6500\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6469\" data-end=\"6499\"\u003eTestosterone (therapeutic)\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-start=\"6500\" data-end=\"6528\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6502\" data-end=\"6526\"\u003eEnobosarm (ostarine)\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6547\" data-end=\"7062\"\u003e\n\u003ctr data-start=\"6547\" data-end=\"6627\"\u003e\n\u003ctd data-start=\"6547\" data-end=\"6560\" data-col-size=\"sm\"\u003eRoute \u0026amp; t½\u003c\/td\u003e\n\u003ctd data-start=\"6560\" data-end=\"6580\" data-col-size=\"sm\"\u003eOral; \u003cstrong data-start=\"6568\" data-end=\"6579\"\u003e24–36 h\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"6580\" data-end=\"6610\" data-col-size=\"sm\"\u003eIM\/SC\/transdermal; variable\u003c\/td\u003e\n\u003ctd data-start=\"6610\" data-end=\"6627\" data-col-size=\"sm\"\u003eOral; 24–36 h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6628\" data-end=\"6739\"\u003e\n\u003ctd data-start=\"6628\" data-end=\"6658\" data-col-size=\"sm\"\u003eLean-mass gain (short term)\u003c\/td\u003e\n\u003ctd data-start=\"6658\" data-end=\"6685\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6660\" data-end=\"6684\"\u003eYes (≈1 kg in 3 wks)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6685\" data-end=\"6708\" data-col-size=\"sm\"\u003eYes (dose-dependent)\u003c\/td\u003e\n\u003ctd data-start=\"6708\" data-end=\"6739\" data-col-size=\"sm\"\u003eYes (RCTs in illness\/aging)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6740\" data-end=\"6811\"\u003e\n\u003ctd data-start=\"6740\" data-end=\"6763\" data-col-size=\"sm\"\u003eHPG-axis suppression\u003c\/td\u003e\n\u003ctd data-start=\"6763\" data-end=\"6778\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6765\" data-end=\"6777\"\u003eModerate\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6778\" data-end=\"6799\" data-col-size=\"sm\"\u003eMarked (exogenous)\u003c\/td\u003e\n\u003ctd data-start=\"6799\" data-end=\"6811\" data-col-size=\"sm\"\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6812\" data-end=\"6871\"\u003e\n\u003ctd data-start=\"6812\" data-end=\"6828\" data-col-size=\"sm\"\u003eHDL reduction\u003c\/td\u003e\n\u003ctd data-start=\"6828\" data-end=\"6841\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6830\" data-end=\"6840\"\u003eCommon\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"6841\" data-end=\"6852\" data-col-size=\"sm\"\u003eVariable\u003c\/td\u003e\n\u003ctd data-start=\"6852\" data-end=\"6871\" data-col-size=\"sm\"\u003eCommon (milder)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6872\" data-end=\"6946\"\u003e\n\u003ctd data-start=\"6872\" data-end=\"6887\" data-col-size=\"sm\"\u003eProstate\/PSA\u003c\/td\u003e\n\u003ctd data-start=\"6887\" data-end=\"6911\" data-col-size=\"sm\"\u003eLow change short-term\u003c\/td\u003e\n\u003ctd data-start=\"6911\" data-end=\"6932\" data-col-size=\"sm\"\u003eIncreases possible\u003c\/td\u003e\n\u003ctd data-start=\"6932\" data-end=\"6946\" data-col-size=\"sm\"\u003eLow change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6947\" data-end=\"7062\"\u003e\n\u003ctd data-start=\"6947\" data-end=\"6971\" data-col-size=\"sm\"\u003eHepatotoxicity signal\u003c\/td\u003e\n\u003ctd data-start=\"6971\" data-end=\"7003\" data-col-size=\"sm\"\u003e\u003cstrong data-start=\"6973\" data-end=\"7002\"\u003eCase reports (real-world)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd data-start=\"7003\" data-end=\"7025\" data-col-size=\"sm\"\u003eLow (non-17-α oral)\u003c\/td\u003e\n\u003ctd data-start=\"7025\" data-end=\"7062\" data-col-size=\"sm\"\u003eLow–moderate (case reports exist)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"7064\" data-end=\"7067\"\u003e\n\u003ch2 data-start=\"7069\" data-end=\"7095\"\u003e7. Regulatory Landscape\u003c\/h2\u003e\n\u003cul data-start=\"7097\" data-end=\"7500\"\u003e\n\u003cli data-start=\"7097\" data-end=\"7149\"\u003e\n\u003cp data-start=\"7099\" data-end=\"7149\"\u003e\u003cstrong data-start=\"7099\" data-end=\"7113\"\u003eApprovals:\u003c\/strong\u003e \u003cstrong data-start=\"7114\" data-end=\"7122\"\u003eNone\u003c\/strong\u003e (no medical indication).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7150\" data-end=\"7269\"\u003e\n\u003cp data-start=\"7152\" data-end=\"7269\"\u003e\u003cstrong data-start=\"7152\" data-end=\"7168\"\u003eEnforcement:\u003c\/strong\u003e \u003cstrong data-start=\"7169\" data-end=\"7185\"\u003eFDA warnings\u003c\/strong\u003e against SARM-containing “supplements”; multiple \u003cstrong data-start=\"7234\" data-end=\"7258\"\u003eproduct adulteration\u003c\/strong\u003e recalls.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7270\" data-end=\"7414\"\u003e\n\u003cp data-start=\"7272\" data-end=\"7414\"\u003e\u003cstrong data-start=\"7272\" data-end=\"7282\"\u003eSport:\u003c\/strong\u003e \u003cstrong data-start=\"7283\" data-end=\"7302\"\u003eWADA-prohibited\u003c\/strong\u003e (S1 Anabolic Agents). \u003cstrong data-start=\"7325\" data-end=\"7343\"\u003ePositive tests\u003c\/strong\u003e often arise from contaminated supplements; strict liability applies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7415\" data-end=\"7500\"\u003e\n\u003cp data-start=\"7417\" data-end=\"7500\"\u003e\u003cstrong data-start=\"7417\" data-end=\"7442\"\u003eClinical development:\u003c\/strong\u003e Limited, with no recent pivotal trials publicly reported.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7502\" data-end=\"7505\"\u003e\n\u003ch2 data-start=\"7507\" data-end=\"7530\"\u003e8. Future Directions\u003c\/h2\u003e\n\u003cul data-start=\"7532\" data-end=\"8075\"\u003e\n\u003cli data-start=\"7532\" data-end=\"7636\"\u003e\n\u003cp data-start=\"7534\" data-end=\"7636\"\u003e\u003cstrong data-start=\"7534\" data-end=\"7562\"\u003eLong-term safety studies\u003c\/strong\u003e (lipids, liver, prostate, mood\/CNS) with standardized, GMP drug supply.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7637\" data-end=\"7753\"\u003e\n\u003cp data-start=\"7639\" data-end=\"7753\"\u003e\u003cstrong data-start=\"7639\" data-end=\"7663\"\u003eElderly\/frailty RCTs\u003c\/strong\u003e pairing LGD-4033 with \u003cstrong data-start=\"7686\" data-end=\"7721\"\u003eprogressive resistance training\u003c\/strong\u003e and \u003cstrong data-start=\"7726\" data-end=\"7750\"\u003eprotein optimization\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7754\" data-end=\"7811\"\u003e\n\u003cp data-start=\"7756\" data-end=\"7811\"\u003e\u003cstrong data-start=\"7756\" data-end=\"7779\"\u003eBone-focused trials\u003c\/strong\u003e (DXA\/BCT, microarchitecture).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7812\" data-end=\"7936\"\u003e\n\u003cp data-start=\"7814\" data-end=\"7936\"\u003e\u003cstrong data-start=\"7814\" data-end=\"7837\"\u003eBiomarker strategy:\u003c\/strong\u003e \u003cstrong data-start=\"7838\" data-end=\"7896\"\u003eIGF-1, myostatin, CK, lipid panel, LH\/FSH\/testosterone\u003c\/strong\u003e, and \u003cstrong data-start=\"7902\" data-end=\"7915\"\u003ectDNA\/PSA\u003c\/strong\u003e where appropriate.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7937\" data-end=\"8075\"\u003e\n\u003cp data-start=\"7939\" data-end=\"8075\"\u003e\u003cstrong data-start=\"7939\" data-end=\"7963\"\u003eMedicinal chemistry:\u003c\/strong\u003e Next-gen SARMs with \u003cstrong data-start=\"7984\" data-end=\"8022\"\u003eimproved anabolic:androgenic ratio\u003c\/strong\u003e, \u003cstrong data-start=\"8024\" data-end=\"8044\"\u003elipid neutrality\u003c\/strong\u003e, and \u003cstrong data-start=\"8050\" data-end=\"8074\"\u003ehepatobiliary safety\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"8077\" data-end=\"8080\"\u003e\n\u003ch3 data-start=\"8082\" data-end=\"8105\"\u003eSelected References\u003c\/h3\u003e\n\u003cul data-start=\"8107\" data-end=\"8853\"\u003e\n\u003cli data-start=\"8107\" data-end=\"8250\"\u003e\n\u003cp data-start=\"8109\" data-end=\"8250\"\u003eBasaria S. et al. \u003cstrong data-start=\"8127\" data-end=\"8215\"\u003eSafety, PK\/PD, and body-composition effects of LGD-4033 in healthy men (21-day RCT).\u003c\/strong\u003e \u003cem data-start=\"8216\" data-end=\"8248\"\u003eJ Gerontol A Biol Sci Med Sci.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8251\" data-end=\"8378\"\u003e\n\u003cp data-start=\"8253\" data-end=\"8378\"\u003eDalton J.T., Kearbey J.D., et al. \u003cstrong data-start=\"8287\" data-end=\"8350\"\u003eNonsteroidal SARMs: pharmacology and therapeutic prospects.\u003c\/strong\u003e \u003cem data-start=\"8351\" data-end=\"8376\"\u003eJ Med Chem; Endocr Rev.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8379\" data-end=\"8494\"\u003e\n\u003cp data-start=\"8381\" data-end=\"8494\"\u003eGao W., et al. \u003cstrong data-start=\"8396\" data-end=\"8462\"\u003eSARMs in muscle and bone—preclinical efficacy and selectivity.\u003c\/strong\u003e \u003cem data-start=\"8463\" data-end=\"8492\"\u003eJ Pharmacol Exp Ther; JBMR.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8495\" data-end=\"8616\"\u003e\n\u003cp data-start=\"8497\" data-end=\"8616\"\u003eEvans N.A., Hasenoehrl T. \u003cstrong data-start=\"8523\" data-end=\"8578\"\u003eAndrogens, erythropoiesis, and cardiovascular risk.\u003c\/strong\u003e \u003cem data-start=\"8579\" data-end=\"8614\"\u003eHematology; Circulation Research.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8617\" data-end=\"8722\"\u003e\n\u003cp data-start=\"8619\" data-end=\"8722\"\u003eDrug Testing \u0026amp; Analysis \/ WADA Lab Reports. \u003cstrong data-start=\"8663\" data-end=\"8720\"\u003eLGD-4033 long-term metabolites and detection windows.\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"8723\" data-end=\"8853\"\u003e\n\u003cp data-start=\"8725\" data-end=\"8853\"\u003eCase reports\/series of \u003cstrong data-start=\"8748\" data-end=\"8780\"\u003eSARM-associated liver injury\u003c\/strong\u003e in real-world use. \u003cem data-start=\"8800\" data-end=\"8851\"\u003eHepatology Communications; J Clin Transl Hepatol.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684869140818,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/LGD4033_10mg.png?v=1770834962","url":"https:\/\/sciencepeptideslab.com\/products\/lgd-4033-50x10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}